Back to
Gavi is co-leading COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. This involves coordinating the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of COVID-19 vaccines.
Latest COVAX news
UK-donated COVID-19 vaccine doses reach African countries
The first AstraZeneca doses donated to COVAX by the United Kingdom (UK) will soon arrive in Angola, Egypt, Ethiopia, Ghana, Kenya, Malawi, Nigeria, Senegal and Uganda, with Zambia and DRC set to be the first to receive these UK-donated vaccines…
The Government of the People’s Republic of China (China) has pledged US$100 million to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC). The announcement, made at the International Forum on COVID-19 Vaccine Cooperation, hosted by China,…
First doses donated by Spain through COVAX arrive to Peru, Guatemala, Paraguay and Nicaragua
As part of its pledge to deliver 22.5 million doses of COVID-19 vaccines, the first doses donated by Spain are arriving to countries in Latin America.
New financing agreement boost for malaria vaccine
Gavi, MedAccess and GlaxoSmithKline join forces to guarantee continued production of the RTS,S antigen for the RTS,S/AS01e malaria vaccine.
First Swedish doses delivered through COVAX
As part of a pledge to deliver at least three million doses of COVID-19 vaccines, the first doses donated by Sweden have been delivered to countries this week, with shipments arriving in Kyrgyzstan and Afghanistan
First deliveries of Norway-donated COVID-19 vaccines to COVAX
Norway donates first doses to COVAX, with first shipments arriving in Nicaragua and Uganda on 30 July. In total, Norway has pledged 5 million doses to COVAX, as well as US$ 141 million in funding.
COVAX and World Bank to Accelerate Vaccine Access for Developing Countries
COVAX and the World Bank will accelerate COVID-19 vaccine supply for developing countries through a new financing mechanism that builds on Gavi’s newly designed AMC cost-sharing arrangement. This allows AMC countries to purchase doses beyond the…
First doses donated by Japan to COVAX reach lower-income countries
The first COVID-19 vaccine doses donated by Japan to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC) have been shipped, with first shipments set to arrive in Cambodia and Iran on Friday, 23 July, and Bangladesh on Saturday, 24 July.
16 July 2021 – Following close collaboration between the African Union (AU)/ African Vaccine Acquisition Trust (AVAT), COVAX and the United States Government, AU Member States are set to receive approximately 25 million COVID-19 vaccines to…
Gavi signs agreements with Sinopharm and Sinovac for immediate supply to COVAX
Gavi, the Vaccine Alliance announced today that it had signed advance purchase agreements (APAs) with Sinopharm for its “BBIBP-CorV” inactivated virus vaccine against COVID-19 as well as with Sinovac for its inactivated virus vaccine against…
Joint COVAX Statement on the equal recognition of vaccines
Geneva/New York/Oslo, 01 July 2021 – COVAX was built on the principle of equitable access to COVID-19 vaccines to protect the health of people all across the globe. That means protecting their lives and livelihoods, including their ability to…
Gavi signs agreement with Clover Biopharmaceuticals for supply to COVAX
Geneva, 30 June 2021 – Gavi, the Vaccine Alliance announced today that it had signed an advance purchase agreement (APA) with Clover Biopharmaceuticals for its SCB-2019 protein-based adjuvanted vaccine candidate against COVID-19. The agreement…
US-donated vaccine deliveries through COVAX set to begin, with first shipment to Honduras
Geneva, 27 June 2021 – Following announcements in recent weeks of donation pledges by the Biden-Harris Administration, COVAX is preparing to ship doses of COVID-19 vaccines donated to COVAX by the United States Government to protect at-risk…
What does COVAX’s latest supply forecast tell us?
The forecast is encouraging given the supply disruptions COVAX and countries with bilateral deals are currently experiencing, and the general challenges manufacturers are experiencing as they ramp up supply at historic speed and scale.
The Republic of Korea has announced a pledge of US$ 200 million to the Gavi COVAX Advance Commitment (Gavi COVAX AMC), with US$ 100 million to be provided in 2021 and an additional US$ 100 million to be provided in 2022
COVAX welcomes dose sharing commitments for 870 million additional doses to support equitable access to vaccines in 2021 and 2022, with the aim to deliver at least half by the end of 2021.
Gavi welcomes U.S. decision to procure 500 million vaccine doses to be delivered through COVAX
Geneva, 10 June 2021 – Gavi, the Vaccine Alliance, today welcomes the decision by the United States Government to procure 500 million COVID-19 vaccine doses on behalf of the COVAX Facility.
Gavi, the Vaccine Alliance, welcomes the announcement by the United States Government of its strategy for global vaccine sharing, which sets out how it will provide at least 80 million doses of vaccines to the rest of the world – with the…
World leaders unite to commit to global equitable access for COVID-19 vaccines
The Gavi COVAX AMC Summit “One World Protected” virtual event, hosted today by the Government of Japan and Gavi, the Vaccine Alliance, raised US$ 2.4 billion from nearly 40 donor governments, the private sector and foundations, exceeding the…
New Zealand transfers vaccine doses to COVAX – 6 Pacific nations first to benefit
Responding to an urgent need for doses around the world, the Government of New Zealand has pledged to transfer 1.6 million doses allocated through COVAX to lower-income economies.
Call to action to equip COVAX to deliver 2 billion doses in 2021
Countries that are advanced in their vaccination programmes are seeing cases of COVID-19 decline, hospitalisations decrease and early signs of some kind of normality resume. However, the global picture is far more concerning.
Global leaders renew their commitment to address urgency of COVID-19 pandemic
At today’s Global Health Summit, hosted by the European Commission and Italy as chair of the G20, leaders pledged their support to the Gavi COVAX Advance Market Commitment (AMC).
Gavi signs agreement with Johnson & Johnson for supply of its COVID-19 vaccine to COVAX
The signed advance purchase agreement (APA) is for a commitment to purchase 200 million doses of the Johnson & Johnson vaccine, with the goal of them being made available to the COVAX Facility in 2021.
Individuals can now directly fund vaccines for lower-income countries via the Gavi COVAX AMC to help end the pandemic. The platform will give businesses a chance to match employee and customer contributions.
Japan to host Gavi's COVAX Advance Market Commitment (AMC) Summit
Geneva, 12 May 2021 – The Government of Japan yesterday announced that it will host the virtual Gavi COVAX Advance Market Commitment (AMC) Summit on June 2nd 2021. The event, co-hosted by Japanese Prime Minister H.E.
The pledges were announced at Global Citizen’s Vax Live Concert on Saturday, co-hosted by Selena Gomez and featuring messages from Prince Harry, the Duke of Sussex, His Holiness Pope Francis and several Heads of State
Gavi signs agreement with Novavax to secure doses on behalf of COVAX Facility
The signed advance purchase agreement (APA) is for a commitment to purchase 350 million doses of the Novavax vaccine candidate. Deliveries will commence in Q3 2021, upon regulatory approval.
Gavi signs agreement with Moderna to secure doses on behalf of COVAX Facility
The signed advance purchase agreement (APA) is for up to 500 million doses of the COVID-19 vaccine manufactured by Moderna. Supply via the agreement will take place from the second half of 2021 through 2022, with options in place to address the…
Geneva/New York, 26 April 2021 – While immunization services have started to recover from disruptions caused by COVID-19, millions of children remain vulnerable to deadly diseases, the World Health Organization (WHO), UNICEF and Gavi, the Vaccine…
France makes important vaccine dose donation to COVAX
Today, to mark the first year of the creation of the Access to COVID-19 Tools (ACT) Accelerator, President Emmanuel Macron announced that France has begun sharing vaccine doses with COVAX, starting with a first batch of 105,600 doses – with 500,…
Global leaders rally to accelerate access to COVID-19 vaccines for lower-income countries
The “One World Protected” Event, hosted today by the United States and Gavi, the Vaccine Alliance, launched a campaign to raise US$ 2 billion for the global fight against COVID-19.
COVAX reaches over 100 economies, 42 days after first international delivery
The COVAX Facility has now delivered life-saving vaccines to over 100 economies since making its first international delivery to Ghana on February 24th.
Gavi and Save the Children form global partnership to immunise zero-dose and vulnerable children
The partnership will focus on reaching children who are currently receiving no routine vaccines and marginalised communities in line with Gavi’s vision to ‘leave no-one behind with immunisation’.
United States to host launch event for Gavi COVAX AMC 2021 investment opportunity
The virtual event will bring together world leaders, the private sector, civil society, and key technical partners to galvanize resources and commitment to the Gavi COVAX Advance Market Commitment (AMC).
The COVAX Facility has notified participating economies that deliveries of doses from the Serum Institute of India (SII) will be delayed in March and April.
COVAX publishes first round of allocations
Geneva/Oslo/New York, 2 March 2021 – The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organization (WHO), as co-leads of the COVAX initiative for equitable global access to COVID-…
First COVID-19 COVAX vaccine doses administered in Africa
Today, the governments of Côte d’Ivoire and Ghana began COVID-19 vaccination campaigns aimed at protecting healthcare workers
COVAX announces 600,000 doses of the AstraZeneca/Oxford vaccine licensed to Serum Institute of India have arrived in Accra, Ghana; further deliveries to Abidjan, Cote d’Ivoire are expected this week.
No-fault compensation programme for COVID-19 vaccines is a world first
New programme makes compensation available to eligible individuals in 92 low- and middle-income countries without need to resort to law courts.
Today G7 leaders announced a doubling of funding for Gavi COVAX AMC to support lower-income economies obtain life-saving vaccines against COVID-19, ensuring greater equity in fighting to end the acute phase of the pandemic.
Gavi signs memorandum of understanding with Novavax on behalf of COVAX Facility
The signed memorandum of understanding (MoU) between Gavi and Novavax is to make a cumulative volume of 1.1 billion doses of the Novavax vaccine candidate available to the COVAX Facility.
COVAX Statement on WHO Emergency Use Listing for AstraZeneca/Oxford COVID-19 Vaccine
Geneva / New York / Oslo – 15 February 2021 The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organisation (WHO), as co-leads of the COVAX initiative for equitable global access to…
COVAX Statement on New Variants of SARS-CoV-2
The emergence of variants of SARS-CoV-2, the virus that causes COVID-19, serve as a powerful reminder that viruses by their very nature mutate, and that the scientific response may need to adapt if they are to remain effective against them.
COVAX publishes first interim distribution forecast
Geneva/Oslo/New York, 3 February 2021 – The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the World Health Organisation, as co-leads of the COVAX initiative for equitable global access to COVID-19 vaccines…
COVAX announces new agreement, plans for first deliveries
COVAX announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer-BioNTech vaccine; rollout to commence with successful execution of supply agreements.
COVAX now has agreements in place to access nearly two billion doses of several promising vaccine candidates, and laid the groundwork for further doses to be secured through contributions from donors.
Gavi Board approves new push to reach unvaccinated children worldwide
Gavi Board approves more than US$ 600 million in new funding to help accelerate efforts to reach ‘zero-dose’ and under-immunised children in the face of the COVID-19 pandemic.
High-risk and vulnerable groups and healthcare workers first in line for successful vaccine.
Gavi and IOM join forces to improve immunisation coverage for migrants
Memorandum of understanding signed today will strengthen collaboration on vaccination efforts and related health services for migrants and forcibly displaced persons across the world
Gavi statement on AstraZeneca/Oxford interim efficacy data
Geneva, 24 November 2020 – Gavi, the Vaccine Alliance, as co-lead of COVAX and administrator of the COVAX Facility, welcomes the release of interim efficacy data for the AstraZeneca/Oxford COVID-19 vaccine candidate.
COVAX Facility convenes first meeting of COVAX AMC engagement group
The COVAX AMC Engagement Group, composed of Gavi COVAX AMC participants, donors, and other stakeholders, forms a key component of Facility governance.
The European Commission, France, Spain, The Republic of Korea and the Bill & Melinda Gates Foundation pledge US$ 360 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC)
COVAX Facility convenes first meeting of COVAX Shareholders Council
The COVAX Shareholders Council, composed of all self-financing participants, forms a key component of Facility governance.
COVAX welcomes appointment of civil society representatives
As part of the global response to the COVID-19 pandemic, COVAX – the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, co-led by Gavi, CEPI, and the WHO – welcomes the appointment of civil society organisation representatives to…
Gavi, the Vaccine Alliance announced today that it had signed a Statement of Intent with Sanofi and GSK to provide 200 million doses of the companies’ adjuvanted recombinant protein COVID-19 vaccine to the COVAX Facility.
Japan pledges US$ 130 million to support global access to COVID-19 vaccines
Japanese Government pledges US$ 130 million in funding to the Gavi COVAX Advance Market Commitment (AMC), bringing the total raised to roughly US$ 1.8 billion.
Countries pledge nearly US$ 1 billion to support equitable access to COVID-19 vaccines
The United Kingdom, Canada, Germany, Italy and Sweden pledge approximately US$ 960 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC)
The Gavi Board has approved the provision of US$ 150 million in initial funding to jumpstart support COVAX AMC-eligible countries’ readiness to deliver COVID-19 vaccines, in the form of planning, technical assistance and cold chain equipment
Collaboration among the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation will accelerate manufacturing and delivery of up to an additional 100 million doses of future vaccines, if proven to be…
Boost for global response to COVID-19 as economies worldwide formally sign up to COVAX Facility
64 higher income economies have now joined the COVAX Facility, with a further 38 economies expected to sign in the coming days
Australia commits AU$ 80 million to guarantee access to COVID-19 vaccines for all
The funding will support the Gavi COVAX Advance Market Commitment (AMC), which aims to secure doses of COVID-19 vaccines for 92 low- and middle-income countries and economies at the same time as wealthier nations
172 countries & multiple candidate vaccines engaged in COVID-19 Vaccine Global Access Facility
Goal of bringing the pandemic under control via equitable access to COVID-19 vaccines needs urgent, broadscale commitment and investment from countries
CSOs will play a vital role in the development and implementation of the COVAX initiative as well as the deployment of any successful vaccine through COVAX.
New landmark collaboration between the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation to accelerate manufacturing and delivery of up to 100 million doses of future safe and effective COVID-…
Gavi Board agrees scope of COVAX Advance Market Commitment (AMC), which aims to secure doses of COVID-19 vaccines for 92 low- and middle-income countries and economies at the same time as wealthier nations.
More than 150 countries engaged in COVID-19 vaccine global access facility
Seventy-five countries submit expressions of interest to COVAX Facility, joining up to 90 further countries which could be supported by the COVAX Advance Market Commitment (AMC)
Global technology company TransferWise and a donor which asked to remain anonymous made significant financial commitments to Gavi’s Advance Market Commitment for COVID-19 Vaccines (Gavi COVAX AMC)
Gavi Board calls for global access to COVID-19 vaccines
Gavi Board shows support for continued work on COVAX Facility: a global, coordinated mechanism designed to ensure rapid and equitable access to safe and efficacious COVID-19 vaccines to as broad a global population as possible
Gavi launches innovative financing mechanism for access to COVID-19 vaccines
Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC) launched at Global Vaccine Summit 2020 draws strong support, early commitments from global leaders.
What is COVAX?
COVAX is the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator
The ACT Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines.
COVAX is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi and the World Health Organization (WHO), alongside key delivery partner UNICEF. Its aim is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world.
For any enquiries about the COVAX Facility, please contact covax@gavi.org.
COVAX Humanitarian Buffer
The Humanitarian Buffer is a mechanism established within the COVAX Facility to act as a measure of ‘last resort’ to ensure access to COVID-19 vaccines for high-risk and vulnerable populations in humanitarian settings. Populations of concern in humanitarian settings may include refugees, asylum seekers, stateless persons, internally displaced persons, minorities, populations in conflict settings or those affected by humanitarian emergencies, and vulnerable migrants irrespective of their legal status. Both COVAX Participants and humanitarian agencies can apply for Humanitarian Buffer doses.
N.B. While application review, approval, prioritisation and allocation will be undertaken on an ongoing basis by the IASC decision-making body, applicants are advised that shipment of doses is contingent on available supply and successful contracting with manufacturers:
-
Supply constraints affecting the COVAX Facility will also impact the availability of doses to the Humanitarian Buffer.
-
Shipments for humanitarian agencies, including UN organisations, Red Cross and Red Crescent, International and national non-governmental and civil society organisations, are subject to successful conclusion of contracts with manufacturers, including on indemnity and liability-related arrangements.
Applying for the COVAX Humanitarian Buffer
COVAX Humanitarian Buffer applications are for doses, devices and delivery funding, as required. For any questions, or to submit an application, please contact COVAX_Humanitarian_Buffer@gavi.org.
Why we need COVAX
Developing a vaccine against COVID-19 is the most pressing challenge of our time - and nobody wins the race until everyone wins.
The global pandemic has already caused the loss of hundreds of thousands of lives and disrupted the lives of billions more. As well as reducing the tragic loss of life and helping to get the pandemic under control, introduction of a vaccine will prevent the loss of US$ 375 billion to the global economy every month. Global equitable access to a vaccine, particularly protecting health care workers and those most-at-risk is the only way to mitigate the public health and economic impact of the pandemic.
What COVAX offers
Doses for at least 20% of countries' populations
Diverse and actively managed portfolio of vaccines
Vaccines delivered as soon as they are available
End the acute phase of the pandemic
Rebuild economies
Gavi's role in COVAX
- COVAX Facility
Gavi is coordinating the development and implementation of the COVAX Facility, the global procurement mechanism of COVAX. The COVAX Facility will make investments across a broad portfolio of promising vaccine candidates (including those being supported by CEPI) to make sure at-risk investment in manufacturing happens now. This means the COVAX Facility, by pooling purchasing power from all countries that participate, will have rapid access to doses of safe and effective vaccines as soon as they receive regulatory approval. Guided by an allocation framework being developed by WHO, the COVAX Facility will then equitably distribute these doses to help protect the most at-risk groups in all participating countries.
Gavi is coordinating the development and implementation of the COVAX AMC, the financing instrument that will support the participation of 92 lower-middle and low-income economies in the COVAX Facility. The COVAX AMC is critical to ensuring equitable access to COVID-19 vaccines, regardless of income level – and requires an urgent investment of US$ 2 billion, from sovereign donors, philanthropies and the private sector, by the end of 2020. The COVAX AMC and associated support to the eligible countries that apply will build on Gavi’s two decades of experience delivering life-saving vaccines to more than half of the world’s population, including in the hardest to reach communities.
- Country readiness & delivery
Gavi is working with Alliance partners UNICEF and WHO to ensure that the infrastructure is in place, and the technical support available, to make sure COVID-19 vaccines can be safely delivered to all those who need them. Gavi is also part of the health systems work of the ACT-Accelerator effort, focusing on areas where it has expertise and experience, such as cold chain.
Key COVAX articles
View moreIf we’re not careful, booster vaccines could end up giving the coronavirus a boost
The sooner we start using booster jabs, the more likely it is that we will need them.
Intellectual Property and COVID-19 vaccines
During a pandemic supply bottlenecks of essential medical products are almost inevitable, but with COVID-19 this has been further exacerbated by governments hoarding doses and imposing export bans.
Refugees included in Uganda’s COVID-19 vaccine drive
Uganda is setting an example by including its estimated 1.4 million refugees in its COVID-19 vaccine programme, however there are still barriers to overcome.
New vaccination figures underscore urgency to reach the most vulnerable
New data shows the impact COVID-19 is having on routine immunisation programmes worldwide, particularly in lower-income countries. We need action, now, to get routine immunisation programmes back on track and ensure that everyone, everywhere is…
From town criers to local monarchs: encouraging COVID-19 vaccination in Southern Nigeria
Volunteers, including King Dakolo of the Epetiama kingdom, are sensitising and convincing people to accept the COVID-19 vaccine in Bayelsa State, Southern Nigeria.
Nurses on the COVID-19 frontlines in Sierra Leone
#VaccinesWork spoke to nurse Fatmata Kamara* about how the COVID-19 vaccine roll-out in Sierra Leone is progressing.
COVAX documents
Documents
Last updated: 18 Aug 2021